Engflag

Lactobacillus spp.

Quick links to important sections

Lactobacillus spp.

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactobacillus spp.

Understanding Lactobacillus spp.

Lactobacillus is a genus of Gram-positive, rod-shaped, non-spore-forming bacteria. These microorganisms are characterized by their ability to convert sugars into lactic acid through a process known as fermentation. They are a major part of the lactic acid bacteria group and are naturally found in various environments, including the human body.

Natural Presence in the Human Body

Lactobacillus species are significant components of the indigenous microbiota in humans. They primarily colonize the following areas:

  • The Digestive Tract: They reside throughout the gastrointestinal system, particularly in the small and large intestines.
  • The Genitourinary System: They are the dominant microorganisms in the vaginal flora of healthy individuals.
  • The Mouth: They contribute to the complex microbial ecosystem of the oral cavity.

Biological Role

In the human body, Lactobacillus species contribute to the maintenance of a balanced microbial environment. By producing lactic acid, they help maintain an acidic pH in their respective habitats. This acidity serves to create an environment that is less hospitable to the overgrowth of potentially harmful microorganisms.

Beyond pH regulation, these bacteria interact with the epithelial lining of the body's mucosal surfaces. They compete for nutrients and attachment sites, which is a fundamental aspect of how a stable internal ecosystem is maintained.

Common Species

The genus Lactobacillus comprises numerous distinct species. Some of the most frequently identified species in human health contexts include:

  • Lactobacillus acidophilus
  • Lactobacillus rhamnosus
  • Lactobacillus reuteri
  • Lactobacillus casei
  • Lactobacillus plantarum

Fermentation and Food

Outside of the human body, Lactobacillus species are well known for their role in food microbiology. Their fermentative capabilities are utilized globally to produce a variety of fermented foods. During these processes, the production of lactic acid acts as a natural preservative and alters the texture and flavor of the original food source.

Regulatory References

  1. NIH: Probiotics — Usefulness and Safety

What side effects are possible with Lactobacillus spp.?

Possible side effects and safety information

The official safety profile for Lactobacillus species is primarily defined by effects localized to the gastrointestinal system and specific restrictions for high-risk patient groups, as outlined in government regulatory documents.

Adverse Reaction Scope

The majority of documented adverse reactions fall under Gastrointestinal disorders and are frequently classified as common in official reporting. These expected reactions include temporary flatulence, bloating, and mild abdominal discomfort. Regulatory documents sometimes note that these effects may be more prominent at the start of treatment as the body adjusts.

Serious Adverse Reactions are classified as rare but are explicitly documented. The most significant serious risk is sepsis (bacteremia or fungemia), which occurs almost exclusively in highly immunocompromised individuals, such as those who are critically ill, severely debilitated, or have a compromised intestinal barrier. Severe allergic reactions (hypersensitivity) are also noted, though their incidence is not always known.

Population-Specific Safety Considerations

The safety profile includes explicit restrictions for specific populations. Use must be avoided in patients with a known history of hypersensitivity to the active substance. Furthermore, these preparations are contraindicated and should be avoided in severely immunocompromised individuals, including critically ill hospital patients, due to the documented rare risk of systemic infection. Safety concerns have also been raised regarding the use of live microbial products in preterm infants.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lactobacillus species, classified as a biological agent, is defined by the absence of specific, documented toxicological events in regulatory prescribing information. This reflects the agent's inherently high safety margin as a natural commensal organism.

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations No specific symptoms, clinical manifestations, or acute toxicological events resulting from overdosage are formally documented or reported in regulatory labeling.
Emergency-Response Statements Product discontinuation is generally cited as the only action necessary for over-ingestion of the pure agent.
When Immediate Medical Help is Required Immediate emergency action is only formally mandated by regulators when Lactobacillus spp. is co-formulated with or co-administered with other substances that possess documented acute toxicity risks.

Official Overdose Statements:

  • No specific antidote is known or required for the over-ingestion of the pure Lactobacillus species.
  • Management following over-ingestion is limited to general supportive care and monitoring for non-specific patient discomfort, as documented in regulatory texts.
  • Official documents reflect a non-toxicological severity classification due to the lack of established acute toxicity.

The regulatory overdose profile is structured by the absence of formally documented acute toxic effects, leading official authorities to refrain from listing specific symptoms or clinical signs. Consequently, regulators do not mandate specific, acute emergency actions solely for the over-ingestion of the probiotic component. Mandatory instructions to seek immediate medical help are reserved only for scenarios where the product is combined with other known toxic agents.

Therapeutic Uses of Lactobacillus spp.

Quick Facts

  • May be utilized to help manage symptoms of diarrhea associated with antibiotic use or travel.
  • May be used to assist in the management of symptoms linked to irritable bowel syndrome (IBS) and ulcerative colitis.
  • Used in some contexts to support the body's response to certain vaginal infections.

What Lactobacillus spp. Is Utilized For

Lactobacillus species are a group of beneficial bacteria, commonly offered as dietary supplements, that may be used in several therapeutic contexts. These microorganisms are often administered to assist in restoring the body's natural microflora, which may be disrupted by factors like antibiotic use. The primary applications involve the digestive system.

Lactobacillus may be used to help manage symptoms of acute diarrhea, including cases linked to taking antibiotics or traveling. In some individuals, certain strains of Lactobacillus may be incorporated into a regimen to support the management of symptoms associated with irritable bowel syndrome (IBS), such as abdominal pain and discomfort. There is also research suggesting that it may contribute to the management of inflammation in conditions like ulcerative colitis, though more study is needed. Beyond the digestive tract, Lactobacillus may be used to support the body in managing certain vaginal infections and urinary tract infections.

Consulting with a healthcare professional can provide guidance on the appropriate use of these supplements for specific health concerns.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lactobacillus spp.? (Eligibility Profile)

The eligibility profile for products containing live Lactobacillus spp. is determined by official regulatory documents based on a patient's risk of systemic infection (sepsis) from live organisms.

Contraindications and Restrictions

Category Status and Restrictions
Absolute Contraindications Must not use if severely immunocompromised (e.g., undergoing chemotherapy), have central venous catheters, or have known hypersensitivity to product components.
Gastrointestinal Integrity Contraindicated in cases of gastrointestinal perforation or severely damaged mucosal barrier.
Age-Related Use in premature infants is subject to regulatory warnings due to the documented risk of severe infections in hospital settings.
Conditional Use Extreme caution and medical supervision are required for critically ill patients, those with underlying immunosuppressive conditions, and those with severe underlying diseases (e.g., severe acute pancreatitis).
Pregnancy/Lactation Generally considered likely safe for healthy individuals, though strain-specific consultation is recommended.

Eligibility is limited to healthy individuals when no other prohibiting conditions are present. Use is officially prohibited or heavily restricted in populations with compromised immune systems or impaired gastrointestinal barriers.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Lactobacillus spp. (probiotic strains) is primarily governed by its status as a live biological agent, rather than traditional pharmacokinetic mechanisms like CYP-enzyme modulation.

Documented Pharmacodynamic Conflicts

The most significant interaction is a pharmacodynamic conflict with antibiotics. Because antibiotics are designed to kill bacteria, co-administration may reduce or eliminate the viable Lactobacillus strains, thereby diminishing the intended effect of the probiotic product. This is officially documented as an interaction that requires active management.

Interacting Product Category Official Restriction/Condition
Antibiotics (Anti-infective agents) Mandatory Timing Separation is required. The probiotic must be administered at least 2 to 3 hours before or after the dose of the antibiotic.
Immunosuppressants / Antineoplastics Population-Specific Caution is advised for patients who are severely immunocompromised (e.g., undergoing chemotherapy). This is due to the theoretical increased risk of systemic infection from the live cultures.

Absence of Pharmacokinetic Interactions

Official regulatory documents generally do not list specific interactions involving drug-metabolizing enzymes (CYP450 system) or drug transporters (e.g., P-gp) with Lactobacillus spp. There are also no official restrictions documented regarding the use of Lactobacillus spp. with food, alcohol, or herbal products.

Mechanism of Action

The action of Lactobacillus is fundamentally a biological mechanism operating across three core domains: structural integrity, metabolic environment, and immune signaling. This mechanism is primarily peripheral, localizing its effects within the gastrointestinal tract.

Structural Fortification and Competitive Exclusion

Lactobacillus spp. directly modulates Intestinal Epithelial Cells (IECs), promoting the proper assembly and function of tight junction proteins (e.g., Occludin). This leads to reduced paracellular permeability, influencing the epithelial barrier integrity while simultaneously employing competitive exclusion to suppress the adherence of microorganisms sensitive to competitive exclusion.

Biochemical Environment Modulation

The bacteria rapidly ferment available carbohydrates, producing Lactic Acid and Short-Chain Fatty Acids (SCFAs). This activity causes pH acidification, a quick biochemical shift that contributes to the competitive suppression of pH-sensitive pathogenic bacteria, influencing microbial population dynamics.

Immune Signaling Homeostasis

Lactobacillus acts as an immunomodulator by engaging Pattern Recognition Receptors (PRRs) on host immune cells. This interaction influences the cytokine production pathway, often inhibiting the NF-kappa B pathway to promote an anti-inflammatory profile (e.g., increasing IL-10). This biological function modulates signaling associated with local immune homeostasis within the gut mucosa.

Dosage and Administration Information

Lactobacillus species preparations are primarily administered orally in various forms, including capsules, tablets, powders, and granules. The dose is standardized by the content of viable microorganisms, quantified in Colony Forming Units (CFU). Adult dosing regimens typically range from one unit once daily up to multiple units taken several times daily in divided schedules, with potencies spanning from millions to billions of CFU per dose.

Administration Principles

Instruction Domain Standard Administration Principle
Dosing Unit Total viable count expressed in Colony Forming Units (CFU).
Timing Constraint Must be administered at least 2 hours before or after an antibiotic to maintain culture viability.
Ingestion Condition May be taken with or without food. Specialized formulations may instruct taking on an empty stomach.
Preparation Powder or granules must be mixed only with cold liquids or soft food; specialized forms like enteric-coated capsules must be swallowed whole.
Age-Specific Use Administration in pediatric patients often requires the supervision of a medical practitioner. Acceptable dosage forms for children under 3 years are often restricted to liquids or suspensions.

The procedural structure dictates that the preparation’s consistent use relies on adherence to the specified frequency and the critical time separation from co-administered agents. The established framework guides how the living active ingredient must be properly handled and delivered to ensure consistency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lactobacillus spp.

Evidence for Use in Acute and Antibiotic-Related Diarrhea

Research has extensively examined the use of Lactobacillus preparations in individuals, including adults and children, who are experiencing acute diarrhea or diarrhea that was associated with antibiotic use. The evidence base relies heavily on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews and Meta-analyses that examined in these populations. These studies typically monitored outcomes describing episodic or acute changes such as the number of bowel movements and the length of time symptoms were present.

Findings describe patterns observed in these studies where the occurrence or duration of antibiotic-associated diarrhea (AAD) measurements differed in some groups receiving the Lactobacillus preparations. While some studies reported patterns of changes in time to resolution measurements in children, other large, high-quality RCTs reported no clear clinical difference in outcomes. What remains uncertain is the need for larger trials to conclusively determine the most beneficial specific strain, as research suggests effectiveness may be highly dependent on the particular species used. Follow-up durations were typically limited to the course of antibiotic therapy.

Evidence for Use in Managing Symptoms of Irritable Bowel Syndrome (IBS)

Research evaluated the use of Lactobacillus preparations in individuals with Irritable Bowel Syndrome (IBS), a condition characterized by functional limitations and fluctuating or episodic manifestations. Studies are largely comprised of Systematic Reviews and Meta-analyses that examined patient-reported outcomes describing perceived discomfort, including global measures of IBS symptom severity and abdominal pain scores.

Findings describe patterns observed in the studies where some preparations were associated with different scores on global IBS symptom severity compared to control groups. However, the evidence quality varies across studies, and results show patterns of mixed findings. The follow-up durations were limited, and there are insufficient data regarding the durability of any observed changes beyond the study period. Efficacy remains highly strain-specific, leading to considerable data heterogeneity across the evidence landscape.

Key Limitations and Areas of Research Uncertainty

The research base contributes to the broader evidence landscape, but also highlights significant limitations. A key finding is that the results apply only to the populations studied, and the certainty remains low across several indications. A major constraint is strain-specificity, meaning a finding reported for one Lactobacillus strain may not apply to another. Furthermore, evidence quality varies across studies, and many trials have used modest sample sizes or had short follow-up durations, which makes establishing consistent outcomes difficult. The question of whether long-term use is associated with sustained changes is an area where data are still emerging and dedicated research is ongoing.

Key Studies & References 5 Things To Know About Probiotics | NCCIH - NIH

Frequently Asked Questions (FAQ)

Common questions about Lactobacillus spp. (FAQ)

Q: Why is Lactobacillus spp. sometimes listed as a 'dietary supplement' and sometimes a 'drug'?

The classification of a Lactobacillus product as either a drug (medicine) or a dietary supplement depends on its intended use and how it is marketed, according to official regulatory bodies. Products that are advertised with the intent to treat, cure, mitigate, or prevent disease are typically classified and regulated as drugs.

Q: Is Lactobacillus spp. the same as 'probiotics'?

Lactobacillus is a type of microorganism that belongs to the group commonly referred to as probiotics. Official sources describe probiotics as live microorganisms that are defined as providing a health benefit to the host when administered in appropriate amounts, making Lactobacillus one example of a probiotic agent.

Q: Can Lactobacillus spp. be used by children?

Official information describes that the administration in pediatric patients may be subject to supervision by a medical practitioner. Regulatory documents may also specify that certain dosage forms, such as liquids or suspensions, are designated for very young children.

Q: Does being pregnant affect whether I can use Lactobacillus spp.?

For otherwise healthy individuals, products containing Lactobacillus species are generally regarded as likely safe due to the organisms’ long history of use in food. However, official safety assessments advise that health professionals should be aware of its use during pregnancy and lactation and monitor for safety.

Q: Can people who are allergic to milk or dairy use products containing Lactobacillus spp.?

Some regulatory documents and product information sheets explicitly warn that Lactobacillus products should not be used by patients with known allergies to milk or sensitivity to lactose. This is because milk components are frequently used as the growth media for culturing the bacteria.

Q: Is it necessary to store Lactobacillus spp. products in the refrigerator?

The required storage condition is determined by the specific product's stability and strain. Official documents mandate that the product must be stored either refrigerated (e.g., 2 C to 8 C) or at a stated maximum room temperature (e.g., below 25 C) to maintain the viability of the live cultures. Products must not be frozen.

Q: What happens if I forget to take Lactobacillus spp. one day?

Product information typically states that if a dose is missed, it can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, only the next dose should be taken as planned. Double or extra doses are not advised to make up for a missed one.

Q: Is it possible to take too much Lactobacillus spp.?

If an excess amount of the product is suspected, product information advises contacting a poison control center or seeking medical attention. This guidance is consistent with the instructions for other products.

Q: Does the time of day I take Lactobacillus spp. matter?

Official administration instructions focus mainly on two constraints: the mandatory time separation from antibiotics (at least 2 hours) and the option to take it with or without food. Beyond these constraints, regulatory documents do not specify whether the time of day itself (morning versus evening) is critical.

Q: Are there any major food groups I should avoid while using Lactobacillus spp.?

Official regulatory documents generally list no specific restrictions regarding the use of Lactobacillus spp. with food, alcohol, or herbal products. This indicates that official documents do not impose restrictions on avoiding major food groups.

Q: Does alcohol interact with or affect Lactobacillus spp.?

Official drug product documents generally do not list specific restrictions or documented interactions between Lactobacillus spp. and alcohol. The official interaction profile primarily focuses on products that may compromise the live bacterial culture.

Q: Does Lactobacillus spp. interact with common pain relievers like ibuprofen or acetaminophen?

Official regulatory documents typically do not list specific pharmacokinetic interactions—those affecting drug metabolism—with Lactobacillus spp. Consequently, there is no official restriction documented for common, non-antibiotic pain relievers like ibuprofen or acetaminophen.

Q: If I am taking multiple medications, is there a risk of interaction with Lactobacillus spp.?

The most significant interaction officially documented is a pharmacodynamic conflict with antibiotics, which requires strict timing separation to maintain the live cultures. Regulatory sources generally do not list other specific interactions with a wide range of common medications.

Q: Does Lactobacillus spp. interact with birth control pills?

The official interaction profile for Lactobacillus spp. does not list specific conflicts with drug-metabolizing enzymes. Since interactions with birth control pills typically occur through these enzyme systems, an interaction is not officially documented in regulatory sources.

Q: Are there any official warnings about combining Lactobacillus spp. with certain herbal supplements?

Official regulatory documentation generally does not list specific restrictions regarding the use of Lactobacillus spp. with food, alcohol, or herbal products. Documented concerns are focused on antibiotics and immunosuppressants.

Q: Is Lactobacillus spp. generally considered safe for elderly people?

Probiotics have a long history of use and are generally regarded as likely safe for healthy individuals across different age groups. Official safety profiles primarily focus on contraindications for individuals who are severely immunocompromised.

Q: What is the role of Lactobacillus spp. in the 'gut microbiome'?

Official authoritative sources describe Lactobacillus spp. as part of the normal human microbiome. Its role is described as helping the body maintain a healthy community of microorganisms or to assist the internal environment in recovering after it has been disturbed.

Q: Why are there so many different strains of Lactobacillus spp. (like L. acidophilus, L. rhamnosus)?

The research base highlights a constraint known as strain-specificity. This means that the effect reported for one specific Lactobacillus strain may not apply to another, indicating that different strains are recognized to have different actions or evidence.

Q: Do studies suggest Lactobacillus spp. is beneficial for travelers' issues?

Research has examined the use of some probiotic strains, including Lactobacillus, specifically for issues related to traveler’s diarrhea (TD). Some systematic reviews describe patterns where the relative risk of TD was examined, though efficacy is highly specific to the particular strain being used.

Q: What is the long-term evidence for using Lactobacillus spp.?

Official reviews of the research evidence note that follow-up durations in many studies have been limited. There is insufficient data regarding the durability of any observed changes beyond the duration of the study period, which is why long-term evidence is an area of ongoing research.

Q: Can Lactobacillus spp. be given to infants?

Official eligibility profiles caution that the use of live microbial products in infants is subject to strict warnings and is restricted. Documented safety concerns have been raised regarding the risk of severe infections, especially when used in preterm infants and critically ill hospital patients.

Q: Does taking Lactobacillus spp. cause any noticeable changes in the body?

The most common effects documented in official adverse reaction scopes are temporary gastrointestinal discomforts, which include flatulence, bloating, and mild abdominal discomfort. Official documents note that these effects may be more prominent when first starting treatment.

Q: What is the difference between Lactobacillus spp. in yogurt and in a medication?

Products regulated as medicines or supplements are standardized to contain a specific, high count of viable, freeze-dried (lyophilized) cultures, quantified in Colony Forming Units (CFU) for product consistency. Yogurt contains live, active cultures but is regulated as a food product, and its bacterial count is typically not regulated as a medicine.

How should Lactobacillus spp. be stored and disposed of?

How to Store and Dispose of Lactobacillus spp.

The storage of products containing Lactobacillus spp. is strictly regulated to maintain the viability and stability of the live organisms. Official regulatory documents mandate adherence to specific temperature controls (e.g., refrigeration at 2 C to 8 C or storage below 25 C), as determined by product stability studies. Products must be stored in their original, tightly closed containers and often protected from light and moisture to prevent deterioration.

Official Storage and Disposal Requirements

Classification Requirement
Temperature Store refrigerated or below the stated maximum; Do not freeze.
Protection Keep container tightly closed; store in original package to protect from light/moisture.
Disposal Waste that has contacted the microorganism must be decontaminated (e.g., via autoclaving or incineration) prior to disposal into general waste.

Storage must prevent contamination and ensure the product remains viable until the expiry date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lactobacillus spp. found in:

A-Z Index: